Associations of genetic predisposition to Alzheimer’s disease with blood-based biomarkers: a community-based study
This community-based study in rural China demonstrates that genetic predisposition to Alzheimer's disease, driven by APOE ε4 alleles and higher polygenic risk scores, is significantly associated with elevated plasma p-tau217, reduced Aβ42/Aβ40 ratios, and increased markers of neuroinflammation and systemic inflammation, particularly among older adults and females.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Alzheimer's disease is the most common cause of dementia, a condition that slowly erodes memory and thinking skills, affecting millions of people worldwide. While the exact cause of the disease remains complex, scientists know that a person's genetic makeup plays a significant role in their risk. One specific gene, known as APOE, has long been recognized as a major factor; having a certain version of this gene can increase the likelihood of developing the disease, while another version may offer some protection. Beyond this single gene, researchers have also identified many other small genetic variations that, when combined, create a broader picture of risk. To understand how these genetic risks translate into the actual changes happening inside the body, scientists look for biological signals, or biomarkers, in the blood. These markers can reveal early signs of the disease, such as the buildup of harmful proteins or the presence of inflammation, long before symptoms appear. Understanding the link between a person's genes and these blood signals is crucial for figuring out how the disease starts and how it might be stopped.
A team of researchers recently set out to explore these connections in a large group of older adults living in rural China. They studied nearly 4,000 people aged 60 and older, examining their genetic profiles and comparing them to various substances found in their blood. The goal was to see if people with a higher genetic risk for Alzheimer's showed different levels of specific proteins and inflammatory markers compared to those with lower risk. The researchers focused on three main categories of blood markers: those indicating the presence of Alzheimer's-related proteins, those showing signs of nerve damage, and those reflecting inflammation in the body and brain. They measured these markers using highly sensitive tests that can detect tiny amounts of these substances in a simple blood sample.
The study revealed a clear pattern linking genetic risk to specific changes in the blood. People who carried the high-risk version of the APOE gene, or who had a higher overall genetic risk score, showed higher levels of a specific form of a protein called phosphorylated tau, which is a hallmark of Alzheimer's disease. They also showed a lower ratio of two types of amyloid proteins, another key sign of the disease. In addition to these protein changes, these individuals had higher levels of a marker called GFAP, which indicates that the support cells in the brain are reacting to stress or damage, a process known as neuroinflammation. They also showed signs of chronic, low-grade inflammation throughout the rest of their bodies. Interestingly, the researchers found that having a protective version of the APOE gene was linked to lower levels of the harmful tau protein. However, the study did not find a strong connection between these genetic risks and other markers of nerve cell damage, such as total tau or neurofilament light chain, suggesting that the earliest genetic signals are more closely tied to the specific proteins of Alzheimer's and the body's inflammatory response than to general nerve cell death.
The researchers also discovered that these genetic effects were not the same for everyone. The links between genetic risk and the blood markers were stronger in women than in men for some of the protein measures, and stronger in men for others. Furthermore, the associations were much more pronounced in people aged 75 and older compared to those who were younger. This suggests that the biological impact of these genes may become more visible as people age and that the way genes influence the disease might differ between men and women. The study was conducted in a community setting rather than a hospital, which means these findings reflect what happens in the general population, not just in people who are already sick. By showing that genetic risk is tied to specific, measurable changes in the blood, this research helps paint a clearer picture of the biological pathways that lead to Alzheimer's, offering new clues for how to detect and perhaps prevent the disease in its earliest stages.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.